coadministered cagrilintide and semaglutide in adults with overweight or obesity Summary of REDEFINE 1 REDEFINE 2 trials CagriSema, presented this week at #ADA2025 and published NEJM: REDEFINE 1: • 👥 3,417 participants with (without diabetes) treated Combined GLP-1/amylin analog bests monotherapy
Pay in 4 interest-free payments of $6.23 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6



00402-4/asset/7d856d37-1b1d-4481-9723-c6f28077488d/main.assets/gr2_lrg.jpg)






:max_bytes(150000):strip_icc()/Health-GettyImages-2236560849-a1934f1e4c004a19835cb508d021388b.jpg)














